Danielle Curcio

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, David Kallend, Kausik K. Ray et al. · New England Journal of Medicine · 2020 · 801 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial

Stephen J. Nicholls, Marc Ditmarsch, John J.P. Kastelein et al. · Nature Medicine · 2022 · 169 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial)

Kevin C. Maki, David G. Orloff, Stephen J. Nicholls et al. · Clinical Therapeutics · 2013 · 105 citations

Pharmacy, Nutritional Sciences, Pharmacotherapy +17

Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study

Elliot Offman, Ted Marenco, Sandy Ferber et al. · Vascular Health and Risk Management · 2013 · 91 citations · Full text

Pharmacy, Nutritional Sciences, Pharmacokinetics +14

Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk

Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch et al. · New England Journal of Medicine · 2025 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17